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Abstract
Aims/hypothesis This 52-week multinational, randomised,
open-label, parallel-group, non-inferiority trial compared
clinical outcomes following supplementation of oral glu-
cose-lowering drugs with basal insulin analogues detemir
and glargine in type 2 diabetic patients.
Methods Insulin-naive adults (n=582, HbA1c 7.5–10.0%,
BMI≤40.0 kg/m
2) were randomised 1:1 to receive insulin
detemir or glargine once daily (evening) actively titrated to
target fasting plasma glucose (FPG)≤6.0 mmol/l. An
additional morning insulin detemir dose was permitted if
pre-dinner plasma glucose (PG) was >7.0 mmol/l after
achieving FPG<7.0 mmol/l. Due to labelling restrictions,
no second glargine dose was allowed.
Results Baseline HbA1c decreased from 8.6 to 7.2 and
7.1% (NS) with detemir and glargine, respectively. FPG
improved from 10.8 to 7.1 and 7.0 mmol/l (NS), respec-
tively. With detemir, 45% of participants completed the
study on once daily dosing and 55% on twice daily dosing,
with no difference in HbA1c. Overall, 52% of participants
achieved HbA1c≤7.0%: 33% (detemir) and 35% (glargine)
without hypoglycaemia. Within-participant variability for
self-monitored FPG and pre-dinner PG did not differ by
insulin treatment, nor did the relative risk of overall or
nocturnal hypoglycaemia. Modest reductions in weight gain
were seen with detemir vs glargine in completers (3.0 vs
3.9 kg, p=0.01) and in the intention-to-treat population (2.7
vs 3.5 kg, p=0.03), primarily related to completers on once-
dailydetemir.Meandailydetemirdosewashigher(0.78U/kg
[0.52 with once daily dosing, 1.00 U/kg with twice daily
dosing]) than glargine (0.44 IU/kg). Injection site reactions
were more frequent with detemir (4.5 vs 1.4%).
Conclusions/interpretation Supplementation of oral agents
with detemir or glargine achieves clinically important
improvements in glycaemic control with low risk of
hypoglycaemia. Non-inferiority was demonstrated for dete-
mir using higher insulin doses (mainly patients on twice
daily dosing); weight gain was somewhat reduced with
once daily insulin detemir.
ClinicalTrials.gov ID no.: NCT00283751.
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Introduction
People with type 2 diabetes inadequately controlled by oral
glucose-lowering drugs can achieve clinically relevant
improvements in HbA1c with the addition of insulin therapy
[1–3]. However, patients and healthcare providers are often
reluctant to initiate insulin due to concerns over injections,
fear of hypoglycaemia and additional weight gain, and also
because insulin treatment is perceived as complex and an
added burden to diabetes management [4, 5]. Moreover,
once insulin is initiated, recommended targets for glycae-
mic control (HbA1c<6.5–7.0%) are often not met [5–7].
In recent years, the basal insulin analogues glargine and
detemir have been introduced. These were developed to
improve upon the limitations of NPH insulin (NPH) and
other conventional basal insulins, which have an inadequate
duration of action, a marked peak glucose-lowering effect
and variability in response from one injection to another
[8]. These analogues might help to overcome some of the
barriers to insulin initiation and optimisation, including
concerns over hypoglycaemia and weight gain.
Several recent studies have assessed basal insulin as an
add-on therapy to oral glucose-lowering drugs, comparing
either insulin glargine or insulin detemir with NPH, and
using titration algorithms based on glucose monitoring [1,
9–13]. These studies have demonstrated that simple
regimens involving a once or twice daily injection of a
basal insulin analogue can achieve clinically important
improvements in glycaemic control similar to those
achievable with NPH, but with less risk of hypoglycaemia.
Insulin detemir has consistently shown less body weight
gain than NPH when used in this way, as well as when used
in basal plus mealtime insulin therapy [14, 15], whereas a
weight advantage has been reported in only a few of the
comparative trials of glargine vs NPH, as for example in the
recent LANMET study [11].
Insulin glargine is licensed only for once daily use as a
basal insulin for people with diabetes. Insulin detemir, in
contrast, is available for once or twice daily use. Glucose
clamp comparisons between these insulins have given
contradictory information on whether their duration of
effect is comparable [16, 17]. The only direct comparison
in patients with type 2 diabetes suggests very similar
pharmacodynamic profiles at clinically relevant doses [16],
but methodological issues remain controversial. The objec-
tive of the current study was to compare treatment with
insulin detemir and insulin glargine in line with their
licensed indications as add-on therapy to oral glucose-
lowering agents in insulin-naive patients with type 2
diabetes.
Methods
Study protocol This 52-week, parallel-group trial was
conducted in 2003 and 2004 at 80 sites in Europe and the
USA and included 582 insulin-naive people with type 2
diabetes, who were randomised (1:1) and treated with
insulin detemir (Levemir; Novo Nordisk, Bagsværd, Den-
mark) or insulin glargine (Lantus; sanofi-aventis, Paris,
France) as add-on therapy to oral glucose-lowering drugs.
The trial was conducted in accordance with the Declaration
of Helsinki and principles for Good Clinical Practice and
was approved by ethics committees/review boards in all
countries. All participants gave written informed consent.
Concealed randomisation was carried out by an automatic
telephone response system and was stratified according to
oral glucose-lowering drug mono- or combination-therapy at
entry.Anopen-labeldesignwasrequiredtoallow twice daily
administration of insulin detemir if needed, according to the
dosing algorithm targets for pre-dinner plasma glucose (PG)
concentrations (Table 1). Glargine was only administered
once daily at bedtime as per study protocol and in
accordance with its licence [18]. To reduce potential bias,
HbA1c results were only disclosed to investigators at
randomisation and at trial end.
Participants Insulin-naive men and women with type 2
diabetes and the following characteristics were recruited:
≥18 years old, ≥12 months disease duration, BMI≤
40.0 kg/m
2 and HbA1c 7.5–10.0%. For inclusion, they
had to be receiving one or two oral agents (metformin,
insulin secretagogues, α-glucosidase inhibitors) ≥4 months
on at least one-half the maximum recommended dose,
according to local guidelines. Exclusion criteria included
treatment with thiazolidinediones (due to labelling restric-
tions in Europe), use of more than two oral agents within
6 months, hypoglycaemic unawareness or other medical
conditions likely to interfere with trial conduct. Withdrawal
criteria included pregnancy, HbA1c>11.0% after the first
12 weeks of treatment and initiation of medication
interfering with glucose metabolism.
Study medications Oral glucose-lowering therapy, diet and
physical activity were recommended to remain stable
during the study; no meal-time insulin was allowed. Basal
insulin was initiated once daily in the evening at a dose of
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algorithm. In line with its licence, people allocated to
insulin detemir were allowed to receive an additional
morning insulin dose if pre-dinner PG was >7.0 mmol/l,
but only if pre-breakfast PG was <7.0 mmol/l or nocturnal
hypoglycaemia (major episode or PG≤4.0 mmol/l) pre-
cluded achievement of the fasting plasma glucose (FPG)
target. Insulin detemir was administered with a pen-injector
(FlexPen, Novo Nordisk) 1 h before to 1 h after dinner, and
if needed within 30 min of breakfast. Glargine was given
once daily at bedtime, via a pen-injector in the EU (OptiPen
Pro 1, sanofi-aventis) and with syringes in the USA. The
evening dose of insulin detemir was administered some-
what earlier than that of insulin glargine, to allow for the
possibility that recipients might be switched to a twice daily
schedule, in which case a more even distribution of the
dose across 24 h would be achieved.
Titration of basal insulin Participants attended 16 sched-
uled visits and nine telephone contacts over 1 year. Evening
insulin doses were titrated throughout the trial to a FPG
target ≤6.0 mmol/l in the absence of hypoglycaemia. An
identical pre-dinner glucose target was applied for people
administering a morning dose of insulin detemir (Table 1).
Participants measured capillary PG using glucose meters
(Medisense Xtra; Abbott, Wiesbaden, Germany). Dose
adjustments were to be based on the average of three self-
measurements before breakfast (and before dinner if on
twice daily insulin detemir). During the first 12 weeks,
participants had weekly investigator contact. A titration
committee monitored the algorithm for insulin dose
optimisation and reviewed prescribed insulin doses period-
ically. This committee was not informed of the treatment
insulin being used, but this would have been evident for
participants on twice daily insulin detemir.
Outcome measures The primary endpoint was baseline-
adjusted HbA1c at end of treatment. Secondary variables
included clinic FPG, within-participant variation in PG, ten-
point self-measured PG profiles, proportion of participants
achieving HbA1c≤7.0% with and without hypoglycaemia,
change in body weight, incidence of hypoglycaemia,
adverse events and standard safety parameters.
Analyses and assessments HbA1c was analysed by HPLC
(Bio Rad, Munich, Germany [EU analyses] and Bio Rad,
Hercules, CA, USA [US analyses], DCCT-harmonised),
with a reference range 4.3–6.1%. Clinic FPG was measured
centrally by a hexokinase method (Gluco-quant; Roche,
Mannheim, Germany). Body weight was measured using
calibrated scales. Participants recorded ten-point PG profiles
during the last week of treatment. Hypoglycaemia was
classified as ‘major’ if assistance from another person was
required, ‘minor’ if confirmed by PG<3.1 mmol/l or ‘symp-
toms only’ if PG≥3.1 mmol/l or no measurement was made.
Statistical analyses The sample size was based on non-
inferiority of insulin detemir relative to insulin glargine for
HbA1c after 52 weeks. To achieve a power of 95% with an
expected SD for change in HbA1c of 1.1% and allowing a
dropout rate of 15%, it was originally planned to randomise
466 patients. However, this was extended to 566 patients to
allow for potential regional differences between the EU and
US. The possibility of a treatment × region interaction was
tested, but eliminated from the model as no significant
interaction was found. Non-inferiority was accepted if the
upper limit of the two-sided 95% CI for the difference in
HbA1c (detemir–glargine) was less than 0.4%-units, a value
decided in discussion with the Food and Drug Administra-
tion (FDA) for the entire insulin detemir phase III study
programme.
Unless otherwise specified, all analyses were based on
the intention-to-treat (ITT) population, this being all
randomised patients exposed to insulin detemir or insulin
glargine. A significance level of 5% was used for all
analyses. Participants were regarded as being on once- or
Table 1 Algorithm used for insulin dose titration
Algorithm Adjustment of insulin dose (U)
If positive
response to previous
dose adjustment
If no response
to previous dose
adjustment
a
Evening insulin dose adjustment
Average pre-breakfast self-monitored PG
>10.0 mmol/l +12 +12
9.1–10.0 mmol/l +8 +10
8.1–9.0 mmol/l +6 +8
7.1–8.0 mmol/l +4 +6
6.1–7.0 mmol/l +2 +2
If one self-monitored PG measurement
3.1–4.0 mmol/l −2 –2
<3.1 mmol/l −4 –4
Morning insulin dose adjustment
b
Average pre-dinner self-monitored PG
>10.0 mmol/l +8 +8
9.1–10.0 mmol/l +6 +8
8.1–9.0 mmol/l +4 +6
7.1–8.0 mmol/l +2 +4
6.1–7.0 mmol/l +2 +2
If one self-monitored PG measurement
3.1–4.0 mmol/l –2 –2
<3.1 mmol/l –4 –4
a Non-responses: the average self-monitored PG level is increased
and/or within the same range as at the last contact
bSome insulin detemir-treated participants only
+, insulin dose titrated up; –, insulin dose titrated down
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trial completion. Statistical analyses were not made for
these subsets of patients, as this was non-randomised and
protocol-determined; results are given for observational
comparison only.
Analyses of HbA1c, clinic FPG and change in weight
after 52 weeks were by ANOVA with treatment, region and
oral glucose-lowering therapy as fixed effects and baseline
(randomisation) value as covariate. The last observation
carried forward (LOCF) principle was specified for HbA1c
and clinic FPG in non-completers treated ≥12 weeks (time
of the first on-treatment measurements). Change in weight
was estimated based on all participants completing the trial.
Additional weight analyses were prepared for the ITT
population, applying the same LOCF principle or using
imputed data, by treatment-specific linear regression, from
week 12 onwards to account for continuing weight change
and limit the influence of differences in withdrawal rates
and times between treatments. Fisher’s exact test was used
to compare the numbers of patients on insulin detemir and
insulin glargine with an HbA1c≤7.0% without symptomatic
hypoglycaemia confirmed by PG <4.0 mmol/l or any single
value <3.1 mmol/l during the last 3 months of treatment.
The ten-point self-monitored PG profiles were analysed
for parallelism using repeated measures ANOVA depending
on treatment, region, oral glucose-lowering therapy, time
and treatment × time interaction as fixed effects. Within-
participant variation in self-measured fasting and pre-dinner
PG was determined from four measurements for each
during the last week of treatment. Hypoglycaemic episodes
during the 52 week treatment period were analysed as
recurrent events in a Cox regression analysis using a
gamma frailty model (Splus 2000; Insightful, Seattle, WA,
USA). Nocturnal episodes (2300 to 0600 hours) were
analysed separately. Adverse events were summarised using
descriptive statistics. All other analyses were performed
using SAS version 8.2 (SAS Institute, Cary, NC, USA).
Results
Participants Of 892 patients screened, 582 were rando-
mised, while 289 did not fulfil the selection criteria and 21
withdrew consent. In each treatment arm, 291 patients were
randomised and treated, of whom 231 (79%) and 252
(87%) completed the trial on insulin detemir and insulin
glargine, respectively (Fig. 1). The higher withdrawal rate
observed with insulin detemir was partly due to adverse
events, ten of which were considered possibly or probably
related to trial drug (Electronic supplementary material
[ESM] Table 1). These included two cases of possible
cutaneous allergy, five of injection site reactions and one
each of injection site inflammation, hypoglycaemia and
weight increase. Adverse event withdrawals with possible
or probable relation to glargine included one case each of
pruritus, myalgia, hyperglycaemia and hypoglycaemia.
Details of all adverse events leading to withdrawal are
provided in ESM Table 2. Other diabetes-related reasons
for withdrawal with insulin detemir included HbA1c 12.0%
(n=1) and multiple hypoglycaemic episodes (n=1). Other
reasons for withdrawal included the closure of a trial site
and various circumstantial events unrelated to the trial
medications.
Baseline characteristics (Table 2) were comparable
between the two treatment groups. Participants completing
the trial on once or twice daily insulin detemir had a
baseline HbA1c of 8.60 and 8.66%, respectively.
Insulin dosing Of participants treated with insulin detemir,
104 (45%) completed the trial on one daily injection, while
129 (55%) administered an additional morning dose. The
majority of patients administering insulin detemir twice
daily (n=103) were transferred to this regimen within
12 weeks of treatment. At the time of transfer, about two-
thirds of the patients adding a morning injection fulfilled
the formal dose transfer guidelines, the other one-third were
changed through investigator discretion. Participants using
insulin detemir twice daily administered about 40% of their
daily insulin dose before breakfast. After 52 weeks the
mean daily dose of insulin detemir (n=227) was 0.78 U/kg
(0.52 U/kg on once daily [n=102] and 1.00 U/kg on twice
daily [n=125]) and the mean daily dose of glargine (n=
248) was 0.44 IU/kg.
Glycaemic control HbA1c decreased by 1.5% with both
insulins and was comparable after 52 weeks at 7.2% (n=
268) and 7.1% (n=275) for detemir and glargine respectively
(Table 3), with an estimated difference of 0.05 (−0.11,
0.21)%, thereby meeting the criteria for non-inferiority for
insulin detemir vs glargine. HbA1c was similar in participants
completing the study on once or twice daily insulin detemir
(7.1 and 7.1%). Clinic FPG was 10.8 mmol/l at baseline in
both arms and was comparable at end of treatment with
insulin detemir and insulin glargine (7.1 and 7.0 mmol/l)
(Table 3). The profile of change in HbA1c and FPG was very
similar (Fig. 2a). Mean self-monitored FPG was comparable
between treatments, being 6.1 mmol/l with insulin detemir
and 6.0 mmol/l with insulin glargine; self-monitored PG pre-
dinner (6.8 and 7.0 mmol/l) was also similar.
Within-participant variation in self-monitored PG pre-
breakfast and pre-dinner did not differ significantly between
insulin detemir and insulin glargine (Table 3). The overall
shape of the ten-point self-monitored PG profiles during
the last week of treatment was parallel for insulin detemir
(n=218) and insulin glargine (n=246) (NS) and appeared
identical, regardless of treatment regimen (Fig. 2b).
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tics of type 2 diabetic
participants
Values are n (%) or mean (SD)
aBefore randomisation
SU, sulfonylurea
Characteristics Detemir Glargine
Randomised/exposed/ITT, n (%) 291 (100) 291 (100)
Men/women, n 166/125 171/120
Ethnicity (n)
Black 22 12
White 250 263
Asian-Pacific islander 7 7
Other 12 9
Oral glucose-lowering drugs, n (%)
Monotherapy 73 (25) 70 (24)
Metformin 32 (11) 33 (11)
Insulin secretagogues 41 (14) 37 (13)
Combination therapy 218 (75) 221 (76)
Metformin + secretagogue 212 215
Metformin + alpha glucosidase inhibitor 3 1
Secretagogue + alpha glucosidase inhibitor 3 4
Secretagogue + secretagogue (SU + glinide) – 1
Age (years) 58.4 (10.2) 59.4 (9.6)
Weight (kg)
a 87.4 (16.6) 87.4 (17.4)
BMI (kg/m
2) 30.6 (4.8) 30.5 (4.6)
Duration of diabetes (years) 9.1 (6.1) 9.1 (6.4)
HbA1c (%)
a 8.64 (0.78) 8.62 (0.77)
C-peptide (nmol/l) 0.87 (0.56) 0.85 (0.55)
Screened: 892 
Randomised: 
582 of 892 
Excluded: 310 
Violating selection criteria: 289 
Withdrew consent: 21 
Allocated and exposed 
Detemir: 291 (100%) 
Allocated and exposed 
Glargine: 291 (100%) 
Withdrawn: 60 (21%) 
Adverse events: 23 (8%) 
Ineffective therapy: 3 (1%) 
Non-compliance: 10 (3%) 
Other reason: 24 (8%) 
Completed: 231 (79%) 
(Primary weight analyses) 
Completers 
Once daily detemir: 104 (45%) 
Twice daily detemir: 127 (55%) 
(All explorative analyses) 
Primary analysis: 268 
(92%) 
(23 excluded as no post-
baseline information) 
Primary analysis: 275 
(94%) 
(16 excluded as no post-
baseline information) 
Completed: 252 (87%) 
(Primary weight analyses) 
Completers 
Once daily glargine: 252 (100%) 
(All explorative analyses) 
Withdrawn: 39 (13%) 
Adverse events: 11 (4%) 
Ineffective therapy: 2 (1%) 
Non-compliance: 15 (5%) 
Other reason: 11 (4%)
Fig. 1 Patient disposition
during the trial and consequent
analysis sets
412 Diabetologia (2008) 51:408–416Of participants in both arms, 52% achieved HbA1c≤
7.0%, while 33% treated with insulin detemir and 35%
treated with insulin glargine did so in the absence of
hypoglycaemia. Fasting and pre-dinner PG targets of
≤6.0 mmol/l were achieved by 25 and 20% of participants
treated with insulin detemir and insulin glargine (NS),
respectively; the pre-breakfast target alone was achieved by
46 and 58% (p<0.01) and the pre-dinner target by 38 and
30%, respectively (p<0.05).
Hypoglycaemia The risk of hypoglycaemia of any type was
comparable between treatments (Table 4). The overall rate
of hypoglycaemia was low at 5.8 vs 6.2 episodes per
patient-year with insulin detemir versus insulin glargine
(relative risk: 0.94 [96% CI 0.71, 1.25]), while the rate of
nocturnal hypoglycaemia was only 1.3 episodes per patient-
year with both insulins. Adjustment for HbA1c did not
affect the outcome of the analyses. Major hypoglycaemic
episodes were rare with both insulins, especially at night,
and could not be statistically analysed.
Body weight Weight gain in participants completing
52 weeks of treatment was lower with insulin detemir (n=
230) than with insulin glargine (n=252) (3.0 [SE=0.4] vs
3.9 [SE=0.4] kg, p=0.01). Change in weight analysed by
LOCF (detemir n=268, glargine n=275) confirmed this
lower weight gain (2.7 vs 3.5 kg, p=0.03), as did analysis
with imputation for non-completers (2.8 vs 3.5 kg, p=
0.04). Patients completing the study on once daily insulin
detemir (n=104) had a weight gain of 2.3 (SE=0.5) kg,
whereas those treated twice daily (n=126) gained 3.7 (SE=
0.4) kg, similar to glargine (Fig. 3).
Fig. 2 Change in HbA1c with time (a). Black circles, insulin detemir;
white circles, insulin glargine. b Mean ten-point self-monitored PG
profiles during the last week of treatment. Triangles, insulin detemir
(once daily); squares, insulin detemir (twice daily); black circles,
insulin detemir (all patients); white circles, insulin glargine
Table 3 Glycaemic control in type 2 diabetic patients treated with insulin detemir or insulin glargine
Detemir Glargine Difference
(95% CI)
(detemir/glargine)
p
value
Completers on
once daily
Completers on
twice daily
All All
Parameters n Mean n Mean n Mean n Mean
HbA1c % (SE)
a 104 7.12 (0.11) 127 7.06 (0.10) 268 7.16 (0.08) 275 7.12 (0.08) 0.05
(–0.11, 0.21)
–
Clinic FPG (mmol/l)
a 104 7.27 (0.31) 127 6.73 (0.25) 268 7.14 (0.21) 272 6.98 (0.21) 0.16
(–0.26, 0.58)
–
HbA1c ≤7.0%, n (%) 103 52 (51) 127 69 (54) 248 129 (52) 259 135 (52) – 1.00
HbA1c ≤7.0% without
hypoglycaemia, n (%)
103 31 (30) 127 48 (38) 248 82 (33) 259 90 (35) – 0.71
Within-participant
variation (mmol/l)
Pre-breakfast (mmol/l)
b 103 0.93 (15.0) 125 1.15 (19.6) 238 1.06 (17.5) 257 1.03 (17.3) – 0.45
Pre-dinner (mmol/l)
b 103 1.27 (19.8) 125 1.84 (26.4) 238 1.60 (23.6) 258 1.55 (22.0) – 0.41
aMean (SE); n=number of patients for whom data are available
bWithin-participant SD (CV%)
Diabetologia (2008) 51:408–416 413Adverse events and other safety measures Serious adverse
events were less frequent with insulin detemir (42 patients
with 47 events) than with glargine (53 patients with 73
events). However, only five serious events with insulin
detemir (two hypoglycaemia, one each of hypothyroidism,
injection-site reaction and a motor vehicle accident) and
four with glargine (three hypoglycaemia, one hyperglycae-
mia) were considered by local investigators to be probably
or possibly related to trial products. A participant treated
with insulin detemir was found dead in bed (no autopsy
report available), but had a history of myocardial infarction.
A patient using glargine was hospitalised after the study for
pulmonary fibrosis and died of cryptogenic fibrosing
alveolitis. Adverse events recorded as serious tended to be
of a wide-ranging disparate nature, with no clear pattern of
between-treatment differences. Full details of all serious
adverse events and events recorded as possibly or probably
related to the study insulins are given as in the ESM
Tables 1, 2, 3, and 4).
The only differences in adverse events, judged as possibly
or probably related to trial drugs, between treatments were:
injection-site disorders (13 patients [4.5%] on insulin detemir
compared with four [1.4%] on glargine), allergic reactions
(three patients on detemir vs one on glargine) and skin
disorders including pruritus and rash (six patients on insulin
detemir vs one on glargine). There were no differences in
standard safety parameters between treatments.
Discussion
The results of this first head-to-head comparison of insulin
detemir and insulin glargine as add-on for treatment with
oral glucose-lowering agents in people with type 2 diabetes
using forced insulin titration suggest that clinically signif-
icant and similar improvements in glycaemic control can be
achieved with both analogues, together with a similarly low
risk of hypoglycaemia. Insulin doses were higher with
insulin detemir overall, partly as a result of the doses used
by those taking it twice daily. The withdrawal rate appeared
to be higher with insulin detemir (21 vs 13%), which was
partly accounted for by adverse events (8 vs 4%), this
excess being primarily due to injection site reactions.
Insulin detemir was associated with a modest relative
reduction in weight gain, consistent with observations in
previous comparisons of this analogue with NPH in type 2
diabetes [12, 13, 19, 20]. In the present study, the between-
treatment difference in weight was primarily accounted for
by those patients completing the study on once-daily
insulin detemir. It is, however, possible that differences in
eating pattern were contributory factors in both the insulin
detemir dosing schedule and the different levels of weight
gain observed between the two insulin detemir dosing
schedules. The mechanism(s) responsible for relatively
lower weight gain observed here and previously with insulin
detemir remain the object of speculation [14, 15, 21, 22].
Table 4 Hypoglycaemic episodes in type 2 diabetic patients treated with insulin detemir or insulin glargine
Events Insulin detemir (n=291) Insulin glargine (n=291) Relative risk
(detemir/glargine) (95% CI)
Participants,
n (%)
Episodes
(n)
Rate
(per patient-year)
Participants,
n (%)
Episodes
(n)
Rate
(per patient-year)
All 182 (63) 1521 5.8 191 (66) 1670 6.2 0.94 (0.71–1.25)
Nocturnal 95 (33) 352 1.3 93 (32) 350 1.3 1.05 (0.69–1.58)
Major 5 (2) 9 0.0 8 (3) 8 0.0 –
Nocturnal 3 (1) 5 0.0 4 (1) 4 0.0 –
Minor 135 (46) 737 2.9 151 (52) 786 2.9 1.05 (0.75–1.46)
Nocturnal 73 (25) 212 0.8 71 (24) 192 0.7 1.17 (0.75–1.83)
Symptoms
only
137 (47) 760 3.0 133 (46) 866 3.2 0.88 (0.61–1.25)
Nocturnal 48 (17) 128 0.5 49 (17) 151 0.6 0.88 (0.50–1.54)
No statistical analyses were performed on the small numbers of major events.
Fig. 3 Mean weight change from baseline at week 52 in patients
completing treatment on insulin detemir once or twice daily (and
overall) and insulin glargine. ***p<0.001; †p<0.012
414 Diabetologia (2008) 51:408–416The present study was designed to compare the two
basal insulin analogues as they had been used in previous
studies and according to label. Thus, insulin glargine was
given once daily at bedtime regardless of glycaemic profile,
while for insulin detemir an option was provided for adding
a second dose, primarily based on pre-dinner blood glucose
level following a structured insulin titration protocol. The
decision to use twice-daily insulin detemir could not be
attributed to hypoglycaemia, as patients who were switched
to a twice-daily regimen had on average 3.7 hypoglycaemic
episodes per patient-year prior to transfer, compared with
4.7 episodes per patient-year in patients completing treat-
ment on once-daily insulin detemir. The frequency of
nocturnal hypoglycaemia was also lower in relevant patients
before transfer (0.7 vs 0.9 episodes per patient-year).
Interestingly, the initiation of insulin with once-daily
insulin detemir has recently been tested by Philis-Tsimikas
et al. in type 2 diabetes patients on oral glucose-lowering
agents, resulting in HbA1c reductions of 1.5% (morning
injection) and 1.6% (evening injection) from baseline
values of 9.1 and 8.9%, respectively [13]. These improve-
ments in glycaemic control approach the magnitude of
HbA1c reduction shown in the current study and in previous
studies of once-daily insulin glargine [9–11], although the
insulin detemir doses were higher at trial-end and the absolute
HbA1c values achieved at trial-end were relatively high.
The design of the current study does not allow definitive
conclusions for comparison of once and twice daily dosing
with insulin detemir, although these post hoc observations
do suggest that once daily administration can be an
appropriate starting regimen for people using insulin
detemir as add-on to oral glucose-lowering drug therapy.
However, with dose optimisation, a significant proportion
of patients may eventually need a twice-daily regimen,
guided by structured glucose monitoring. Further studies
are required to better define the differences between these
two basal insulin analogues on the basis of a similar insulin
administration regimen, once daily only, for both insulins.
Alternatively, if the option of adding a second insulin dose
is available for both insulins, then a properly designed
study protocol should allow addition of this second insulin
injection only when a normal or much lower FPG target is
achieved. Indeed, the use of lower FPG targets (e.g.
≤5.5 mmol/l, as has been used previously) should also
enable a higher proportion of patients to reach guideline
HbA1c targets.
In conclusion, the use of insulin detemir or insulin glargine
as add-on to oral glucose-lowering therapy resulted in
comparable HbA1c improvements and a similarly low risk
ofhypoglycaemia.Furthercomparisonsofdetemirandglargine
arerequiredtofullyunderstandhow eachmayrelativelybenefit
defined groups of patients starting on insulin.
Acknowledgements The investigators and participants are thanked
for their participation. A full list of investigators can be seen in the
ESM 1. The study was funded and monitored by Novo Nordisk. The
authors and/or their institutions received support from Novo Nordisk
(J. Larsen and C. Koenen are employees) and Aventis (now sanofi
aventis) for consultation/research/teaching activities. The authors
thank T. Rambrand, M. Edmunds and C. Jones for assistance with
manuscript preparation. An abstract based on feasibility of titration
data was presented at American Diabetes Association (ADA) meeting
in 2004 (Rosenstock et al. Diabetes 53 (Suppl. 2): A145) and another
abstract reporting the findings was presented at the ADA meeting in
2006 (Rosenstock et al. Diabetes 55(1): A132).
Duality of interest C. Koenen and J. Larsen are employees of Novo
Nordisk. M. Davies has received grants in support of investigator and
internal trials from Servier, Novartis, Novo Nordisk, Pfizer, sanofi-
aventis and Lilly, and has acted as a consultant and/or speaker for
Novartis, Novo Nordisk, sanofi-aventis, Lilly, Merck Sharp & Dohme,
and Servier. P. Home has received consultancy fees and/or honoraria
from Novo Nordisk and sanofi aventis. J. Rosenstock has served on
advisory boards and received honoraria/consulting fees from Pfizer,
sanofi-aventis, Novo Nordisk, Eli Lilly, GlaxoSmithKline, MannKind,
Takeda, Centocor, Johnson & Johnson, Roche and Emisphere, and has
also received grant support from Merck, Pfizer, sanofi aventis, Novo
Nordisk, Eli Lilly, GlaxoSmithKline, Takeda, Novartis, AstraZeneca,
Amylin, Roche, Sankyo and MannKind. G. Shernthaner has no
relevant conflicts of interest.
References
1. Riddle MC (2004) Timely initiation of basal insulin. Am J Med
116:3S–9S
2. Wright A, Burden ACF, Paisey RB, Cull CA, Holman RR, for the
UK Prospective Diabetes Study Group (2002) Sulfonylurea
inadequacy: efficacy of addition of insulin over 6 years in patients
with type 2 diabetes in the UK Prospective Diabetes Study
(UKPDS 57). Diabetes Care 25:330–336
3. Marre M (2002) Before oral agents fail: the case for starting
insulin early. Int J Obes 26(Suppl 3):S25–S30
4. Korytkowski M (2002) When oral agents fail: practical barriers to
starting insulin. Int J Obes 26:S18–S24
5. Davies M (2004) The reality of glycaemic control in insulin
treated diabetes: defining the clinical challenges. Int J Obes Relat
Metab Disord 28(Suppl 2):S14–S22
6. Koro CE, Bowlin SJ, Bourgeois N, Fedder DO (2004) Glycaemic
control from 1988 to 2000 among US adults diagnosed with type
2 diabetes. Diabetes Care 27:17–20
7. Turner RC, Cull CA, Frighi V, Holman RR, for the UK
Prospective Diabetes Study (UKPDS) Group (1999) Glycaemic
control with diet, sulfonylurea, metformin, or insulin in patients
with type 2 diabetes mellitus: progressive requirement for multiple
therapies (UKPDS 49). JAMA 281:2005–2012
8. Heise T, Nosek L, Ronn BB et al (2004) Lower within-subject
variability of insulin detemir in comparison to NPH insulin and insulin
glargine in people with type 1 diabetes. Diabetes 53:1614–1620
9. Riddle MC, Rosenstock J, Gerich J, on behalf of the Insulin
Glargine 4002 Study Investigators (2003) The treat-to-target trial:
randomized addition of glargine or human NPH insulin to oral
therapy of type 2 diabetic patients. Diabetes Care 26:3080–3086
10. Eliaschewitz FG, Calvo C, Valbuena H et al, HOE 901/4013 LA
Study Group (2006) Therapy in type 2 diabetes: insulin glargine vs
Diabetologia (2008) 51:408–416 415NPH insulin both in combination with glimepiride. Arch Med Res
37:495–501
11. Yki-Järvinen H, Kauppinen-Mäkelin R, Tiikkainen M et al (2006)
Insulin glargine or NPH combined with metformin in type 2
diabetes: the LANMET study. Diabetologia 49:442–451
12. Hermansen K, Davies M, Derezinski T, Martinez Ravn G,
Clauson P, Home P (2006) A 26-week, randomized, parallel,
treat-to-target trial comparing insulin detemir with NPH insulin as
add-on therapy to oral glucose-lowering drugs in insulin-naive
people with type 2 diabetes. Diabetes Care 29:1269–1274
13. Philis-Tsimikas A, Charpentier G, Clauson P, Martinez Ravn G,
RobertsVL,ThorsteinssonB(2006)Comparisonofonce-dailyinsulin
detemirwithNPHinsulinaddedtoaregimenoforalantidiabeticdrugs
in poorly controlled type 2 diabetes. Clin Ther 28:1569–1581
14. Home P, Kurtzhals P (2006) Insulin detemir: from concept to
clinical experience. Expert Opin Pharmacother 7:325–343
15. Hermansen K, Davies M (2007) Does insulin detemir have a role
in reducing risk of insulin-associated weight gain. Diabetes Obes
Metab 9:209–217
16. Klein O, Lynge J, Endahl L, Damholt B, Nosek L, Heise T (2007)
Albumin-bound basal insulin analogues (insulin detemir and
NN344): comparable time–action profiles but less variability than
insulinglargineintype 2diabetes. Diabetes ObesMetab 9:290–299
17. Porcellati F, Rossetti P, Busciantella Ricci N et al (2007)
Comparison of pharmacokinetics and dynamics of the long-acting
insulin analogs glargine and detemir at steady state in type 1
diabetes: A double-blind, randomized, crossover study. Diabetes
Care 30:2447–2452
18. sanofi aventis (2005) Lantus label information, NDA 21-081/S-
017. Available from http://www.fda.gov/cder/foi/label/2005/
21081s017lbl.pdf, accessed 1 July 2007
19. Raslova K, Bogoev M, Raz I, Leth G, Gall MA, Hancu N (2004)
Insulin detemir and insulin aspart: a promising basal-bolus
regimen for type 2 diabetes. Diabetes Res Clin Pract 66:193–201
20. Haak T, Tiengo A, Draeger E, Suntum M, Waldhäusl W (2005)
Lower within-subject variability of fasting blood glucose and
reduced weight gain with insulin detemir compared to NPH
insulin in patients with type 2 diabetes. Diabetes Obes Metab
7:56–65
21. Raslova K, Tamer SC, Clauson P, Karl D (2007) Insulin detemir
resultsinlessweightgainthanNPHinsulinwhenusedinbasal-bolus
therapyfortype2diabetesmellitus,andthisadvantageincreaseswith
baseline body mass index. Clin Drug Investig 27:279–85
22. Russell-Jones D, Khan R (2007) Insulin-associated weight gain in
diabetes—causes, effects and coping strategies. Diabetes Obes
Metab 9:799–812
416 Diabetologia (2008) 51:408–416